Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: A phase II study
| Autor: | Getta Fried, Nissim Haim, Moshe Stein |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Time Factors Anthracycline Vomiting medicine.medical_treatment Drug Resistance Administration Oral Phases of clinical research Breast Neoplasms Gastroenterology Drug Administration Schedule Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis Etoposide Aged Aged 80 and over Cisplatin Stomatitis Chemotherapy Antibiotics Antineoplastic business.industry Remission Induction Nausea Combination chemotherapy Middle Aged medicine.disease Metastatic breast cancer Surgery Regimen Treatment Outcome Oncology Pediatrics Perinatology and Child Health Female Nervous System Diseases business medicine.drug |
| Zdroj: | Medical and Pediatric Oncology. 34:10-13 |
| ISSN: | 1096-911X 0098-1532 |
| DOI: | 10.1002/(sici)1096-911x(200001)34:1<10::aid-mpo2>3.0.co;2-a |
| Popis: | Background This phase II study evaluates the antitumor activity and tolerance of cisplatin and prolonged oral administration of etoposide in metastatic breast cancer previously exposed to anthracyclines. Procedure Twenty-seven patients with metastatic breast cancer who developed tumor progression following anthracyclines wer e entered in the study. The patients were treated with combination chemotherapy of cisplatin 50 mg/m2 IV day 1 and oral etoposide 50 mg/m2 days 1–17. Cycles were repeated every 29 days. Results Twenty-six patients were evaluated for toxicity and response. Complete remission was observed in 1 of 26 (4%) patients and partial remission in 12 of 26 (46%). Median duration of response was seven months. Pain relief was noted in 9 of 15 (60%) of the symptomatic patients. Myelosuppression was the major toxicity encountered and four (15%) patients required hospitalization for granulocytopenic fever. Nonhematologic toxicity was mild. Conclusions The combination of cisplatin with prolonged oral etoposide is active and tolerable in the management of patients with relapsed metastatic breast cancer previously treated with an anthracycline-based regimen. Med. Pediatr. Oncol. 34:10–13, 2000. © 2000 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text